Remove topic development
article thumbnail

FDA Accepts sNDA for Tapinarof Cream 1% for Treatment of Atopic Dermatitis

Drug Topics

The ADORING 3 phase 3 development program is currently studying the novel, aryl hydrocarbon receptor agonist as a once-daily, cosmetically elegant, and steroid-free topical cream for adults and children with atopic dermatitis.

FDA 112
article thumbnail

How Will the Extinction of B/Yamagata Impact Global Flu Vaccination Strategies?

Drug Topics

Drug Topics talked with Gregg Sylvester, MD, chief health officer and vice president of medical affairs at CSL Seqirus, about what can we learn from this unique situation to improve future vaccine development and distribution.

Vaccines 201
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Leo scores again in hand eczema with its JAK inhibitor cream

Fierce Pharma

It’s been four years since Japan Tobacco snagged approval in its home country for its topical JAK inhibitor delgoci | It’s been four years since Japan Tobacco snagged approval in its home country for its topical JAK inhibitor delgocitinib to treat atopic dermatitis.

82
article thumbnail

YouTube adds explainer videos on basic first aid, emergency care to search results

Fierce Healthcare

Viewers searching for certain acute health topics can now access short explainer videos at the top of search results from reputable sources, developed in partnership with Mass General Brigham and the Mexican Red Cross.

120
120
article thumbnail

FDA’s Draft Guidance on the Q-Submission Program – A Step in the Wrong Direction

The FDA Law Blog

This hardly provides clarification and seems to limit the topics that could utilize this method of feedback. The draft guidance echoes the existing guidance in that the pre-submission should be limited to 3-4 topics; however, the draft guidance goes further and recommends a limit of 7-10 questions across those topics.

FDA 59
article thumbnail

Tapinarof Cream 1% Shows Positive Topline Results for Treatment of Pediatric Atopic Dermatitis

Drug Topics

According to Dermavant, tapinarof cream 1% is a novel, aryl hydrocarbon receptor agonist in development as a once-daily topical cream.

98
article thumbnail

A startup’s psychedelic delivery tech is grabbing attention. Will pharma listen?

PharmaVoice

Psycheceutical is developing a back-of-the-neck topical treatment for ketamine but believes the delivery route holds promise for far more drugs.

105
105